Advertisement

Digestive Diseases and Sciences

, Volume 46, Issue 5, pp 985–992 | Cite as

Double-Blind, Placebo-Controlled Trial of Famotidine in Children with Abdominal Pain and Dyspepsia

  • Mary C. See
  • Audrey H. Birnbaum
  • Clyde B. Schechter
  • Marvin M. Goldenberg
  • Keith J. Benkov
Article

Abstract

To determine the benefit of using an H2-receptor antagonist in children with abdominal pain and dyspepsia, 25 such children were enrolled in a double-blind, placebo-controlled trial of famotidine. Global and quantitative pain assessments were done before and after each treatment period. The quantitative assessment was calculated based on the abdominal pain score that was the sum of three components. Based on the global evaluation, there was a clear benefit of famotidine over placebo (68% vs 12%). Using the quantitative assessment, however, the mean improvement of the score using famotidine versus placebo was not statistically significant (3.37 ± 3.53 vs 1.66 ± 2.7). There was a significant improvement in this score during the first treatment period regardless of medication used (period effect: P = 0.05). A subset of patients with peptic symptoms demonstrated a significant drug effect that outweighed the period effect (drug effect: P = 0.01; period effect: P = 0.02). We conclude that famotidine subjectively improves the symptoms of children with recurrent abdominal pain but not objectively using the derived score. However, famotidine is significantly more effective than placebo among children with peptic symptoms. The use of this simple scoring scale may facilitate selecting those children who will benefit from H2-receptor antagonist therapy.

recurrent abdominal pain famotidine dyspepsia H2-receptor antagonist 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Apley J, Naish N: Recurrent abdominal pains: a field survey of 1,000 school children. Arch Dis Child 33:165–170, 1958Google Scholar
  2. 2.
    Hyams JS, Hyman PE. Recurrent abdominal pain and the biopsychosocial model of medical practice. J Pediatr 133:473–478, 1998Google Scholar
  3. 3.
    Oster J: Recurrent abdominal pain, headache and limb pains in children and adolescents. Pediatrics 50:429–436, 1972Google Scholar
  4. 4.
    Hyams JS, Burke G, Davis PM, Rzepski B, Andrulonis PA: Abdominal pain and irritable bowel syndrome in adolescents: a community-based study. J Pediatr 129:220–226, 1996Google Scholar
  5. 5.
    Hyams JS, Treem WR, Justinich CJ, Davis P, Shoup M, Burke G: Characterization of symptoms in children with recurrent abdominal pain: resemblance to irritable bowel syndrome. J Pediatr Gastroenterol Nutr 20:209–214, 1995Google Scholar
  6. 6.
    AGA technical review: evaluation of dyspepsia. Gastroenterology 114:582–595, 1998Google Scholar
  7. 7.
    Talley NJ, Colin-Jones D, Koch KL, Koch M, Nyren O, Stanghellini V: Functional dyspepsia: A classification with guidelines for diagnosis and management. Gastroenterol Int 4:145–160, 1991Google Scholar
  8. 8.
    Squires RH Jr, Colletti RB: Indications for pediatric gastrointestinal endoscopy: A Medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 23:107–110, 1996Google Scholar
  9. 9.
    McGrath PA, deVeber LL, Hearn MT: Multidimensional pain assessment in children. In Advances in Pain Research and Therapy, Vol 9. HL Fields, R Dubner, F Cervero, (eds). New York, New York Raven Press, 1985, pp 387–393Google Scholar
  10. 10.
    Wallenstein S, Fischer AC: The analysis of the two-period repeated measurements crossover design with application to clinical trials. Biometrics 33:261–269, 1977Google Scholar
  11. 11.
    Boyle JT: Abdominal pain. In Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis, Management, 2nd ed. WA Walker, PR Durie, JR Hamilton, JA Walker-Smith, JB Watkins, (eds). St. Louis, Missouri, Mosby-Year Book, pp 1996, 205–226Google Scholar
  12. 12.
    Mews CF, Sinatra FR: Abdominal pain. In Pediatric Gastrointestinal Disease. Pathophysiology, Diagnosis, Management. R Wyllie, JS Hyams, (eds). Philadelphia, WB Saunders, 1993, pp 177–186Google Scholar
  13. 13.
    See MC, Goldenberg MM, Barth JA Birnbaum AH, Pittman NS, LeLeiko NS, Benkov KJ: A quantitative tool to assess changes in abdominal pain in children. J Pediatr Gastroenterol Nutr 25:462, 1997 (abstract 81)Google Scholar
  14. 14.
    Brunton LL: Agents for control of gastric acidity and treatment of peptic ulcers. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. JG Hardman, LE Limbird, PB Molinoff, RW Ruddon, (eds). New York, McGraw-Hill Companies, 1996, pp 901–915Google Scholar
  15. 15.
    Talley NJ, Phillips SF. Non-ulcer dyspepsia: Potential causes and pathophysiology. Ann Intern Med 108:865–879, 1988Google Scholar
  16. 16.
    Fisher RS, Parkman HP: Management of non-ulcer dyspepsia. N Engl J Med 339:1376–1381, 1998Google Scholar
  17. 17.
    James LP, Kearns GL: Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. Clin Pharmacokinet 31:103–110, 1996Google Scholar
  18. 18.
    Nagita A, Manago M, Aokis S, Mino M, Suzuki K, Ashida K. Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. Ther Drug Monit 16:444–449, 1994Google Scholar

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  • Mary C. See
    • 1
  • Audrey H. Birnbaum
    • 1
  • Clyde B. Schechter
    • 2
  • Marvin M. Goldenberg
    • 3
  • Keith J. Benkov
    • 1
  1. 1.Department of Pediatrics, Division of Pediatric Gastroenterology, Nutrition and Liver DiseasesMount Sinai Medical CenterNew York
  2. 2.Department of Community MedicineMount Sinai Medical CenterNew York
  3. 3.Department of PharmacyMount Sinai Medical CenterNew York

Personalised recommendations